


1Q FY2026

FINANCIAL RESULTS OVERVIEW





Thank You for Your Attention

Safe Harbor

This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and related financing, share repurchases, dividends, diluted share counts, and currency exchange rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations. The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should," "forecast," "project" and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to

successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the impact relating to or arising from changes to tariffs, import/export or trade policies; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended October 31, 2025.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP measures. Non-GAAP measures exclude charges primarily related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, and net (gain) loss on equity securities. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. With respect to the company's guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no reconciliation to GAAP amounts has been provided.

Agilent 1Q26 Results
 High-single digit growth across 3 largest end markets;
 Excellent replacement cycle momentum w/ high-single digit LC growth



- Revenue of \$1.80B while absorbing ~\$10M impact from late January winter storm in the US
- Operating margin 24.6%⁽²⁾, in line with expectations and setting up expected strong margin progression across FY26

Revenue
\$1.80B
 +7.0% reported
 +4.4% core⁽¹⁾⁽²⁾
 +2.6% FX

Operating Margin
24.6%⁽²⁾
 -50 bps y/y

EPS
\$1.36⁽²⁾
 +4% y/y

Capital Allocation

\$268M operating cash flow
 \$152M to purchase 1.05M shares
 \$93M invested in capex
 \$72M in dividends

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
 (2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

Q1 results led by ACG

A solid start to the year in
a dynamic but healthy
market environment

LDG 16.0% Operating Margin ⁽²⁾	+3% Core Growth ⁽¹⁾⁽²⁾ +5% Reported	<ul style="list-style-type: none">• LC replacement cycle continues with high-single digit growth• Omnis family expansion supporting high-single digit Cancer Dx growth
ACG 31.6% Operating Margin ⁽²⁾	+6% Core Growth ⁽¹⁾⁽²⁾ +9% Reported	<ul style="list-style-type: none">• Altura Ultra Inert LC column launch drives 30%+ bio-column growth• 3 marquee enterprise services wins cement leadership position
AMG 25.8% Operating Margin ⁽²⁾	+4% Core Growth ⁽¹⁾⁽²⁾ +7% Reported	<ul style="list-style-type: none">• Double-digit Spectroscopy growth on strong semiconductor performance• GC replacement cycle momentum, low-single digit growth on tough comp

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

Definitions: LDG: Life Sciences and Diagnostics Markets Group, ACG: Agilent CrossLab Group, AMG: Applied Markets Group, LC: Liquid Chromatography, GC: Gas Chromatography



GEOGRAPHY

PRODUCT TYPE

Strong growth in Asia, stable trends in Europe; Americas impacted by late January winter storm

- Americas
38% of Agilent Revenue⁽²⁾
- Europe
29% of Agilent Revenue⁽²⁾
- Asia-Pacific
33% of Agilent Revenue⁽²⁾



(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.
(2) % of Q1'26 Agilent revenue.



GEOGRAPHY


PRODUCT TYPE

Q1 revenue mix

Replacement cycle strength drives increasing Instruments contribution

- Consumables
Services
Informatics
- Instruments

% of total revenue



Q1 REVENUE High-single digit growth in our 3 largest end markets

LC replacement cycle and GLP-1s drive Pharma strength;
CAM sees excellent performance in Advanced Materials sub-segment


		Q1 Core Growth ⁽¹⁾ Results	Share of Agilent Revenue ⁽²⁾
Pharma	Double-digit growth in biotech, ~50% GLP-1 growth across specialty CDMO and analytical lab businesses	+7%	36%
Diagnostics & Clinical	Expanded Omnis family driving new customer interest in medium throughput labs	+7%	15%
Academia & Government	Cont'd soft instruments in the US on lower NIH funding, solid mid-single ACG growth provides offset	-8%	7%
Chemicals & Advanced Materials	Strong double-digit+ results in the semiconductor space across all geographies	+9%	23%
Environmental & Forensics	Growth in Europe and Asia ex-China offset by soft gov't environmental funding in the U.S. & China	+0%	10%
Food	Double-digit growth ex-China, difficult compare in China against large stimulus last year	-4%	9%

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

(2) % of Q1'26 Agilent revenue.

FY26 Guidance⁽¹⁾


Maintaining core revenue growth⁽²⁾ & margin expansion; increasing EPS due to FX



(1) As of February 25, 2026, based on forecasted currency exchange rates. Presented on a non-GAAP basis.
 (2) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
 (3) The 2024 repurchase program became effective on August 1, 2024 and commenced upon completion of our 2023 repurchase program in September 2025.

2Q26 Guidance⁽¹⁾

Continued MSD+ growth expected in largest end markets



\$5M
Q2

Net Interest +
Other Inc/(Exp)

283M
Q2

Share
Count

(1) As of February 25, 2026, based on forecasted currency exchange rates. Presented on a non-GAAP basis.

(2) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.



Get in touch
with us



investor_relations@agilent.com



www.investor.agilent.com